Bundled care for septic shock: An analysis of clinical trials*

Context: Sepsis bundles have been developed to improve patient outcomes by combining component therapies. Valid bundles require effective components with additive benefits. Proponents encourage evaluation of bundles, both as a whole and based on the performance of each component. Objective: Assess the association between outcome and the utilization of component therapies in studies of sepsis bundles. Data Source: Database searches (January 1980 to July 2008) of PubMed, Embase, and the Cochrane Library, using the terms sepsis, bundles, guidelines, and early goal directed therapy. Data Extraction: Inclusion required comparison of septic adults who received bundled care vs. nonprotocolized care. Survival and use rates for individual interventions were abstracted. Main Results: Eight unblinded trials, one randomized and seven with historical controls, were identified. Sepsis bundles were associated with a consistent (I2 = 0%, p = .87) and significant increase in survival (odds ratio, 1.91; 95% confidence interval, 1.49–2.45; p < .0001). For all studies reporting such data, there were consistent (I2 = 0%, p ≥ .64) decreases in time to antibiotics, and increases in the appropriateness of antibiotics (p ≤ .0002 for both). In contrast, significant heterogeneity was seen across trials for all other treatments (antibiotic use within a specified time period; administration of fluids, vasopressors, inotropes, and packed red blood cells titrated to hemodynamic goals; corticosteroids and human recombinant activated protein C use) (all I2 ≥ 67%, p < .002). Except for antibiotics, sepsis bundle components are still being investigated for efficacy in randomized controlled trials. Conclusion: Bundle use was associated with consistent and significant improvement in survival and antibiotic use. Use of other bundle components changed heterogeneously across studies, making their impact on survival uncertain. However, this analysis should be interpreted cautiously as these studies were unblinded, and only one was randomized.

[1]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[2]  K. Vosti,et al.  The importance of underlying disease in patients with gram-negative bacteremia. , 1968, Archives of internal medicine.

[3]  J. Lewis,et al.  Gram-negative bacteremia. , 1969, The Johns Hopkins medical journal.

[4]  R. Bryant,et al.  Factors affecting mortality of gram-negative rod bacteremia. , 1971, Archives of internal medicine.

[5]  W. R. Mccabe,et al.  Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients , 1980 .

[6]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[7]  D Greenwood,et al.  An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. , 1987, The Quarterly journal of medicine.

[8]  The Society of Critical Care Medicine , 1989 .

[9]  C. Natanson,et al.  Antibiotics versus cardiovascular support in a canine model of human septic shock. , 1990, The American journal of physiology.

[10]  V L Yu,et al.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. , 1991, Annals of internal medicine.

[11]  I. L. Cohen.  Guidelines for the use of innovative therapies in sepsis. , 1993, Critical care medicine.

[12]  J. Gatell,et al.  Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. , 1996, Archives of internal medicine.

[13]  R A Weinstein,et al.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. , 1996, The Journal of infectious diseases.

[14]  G. Parmigiani,et al.  The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Fine,et al.  Quality of care, process, and outcomes in elderly patients with pneumonia. , 1997, JAMA.

[16]  L. Leibovici,et al.  Septic shock in bacteremic patients: risk factors, features and prognosis. , 1997, Scandinavian journal of infectious diseases.

[17]  M. Kollef,et al.  Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  G Sherman,et al.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.

[19]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[20]  M. Biros,et al.  Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. , 2001, The Journal of emergency medicine.

[21]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[22]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[23]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[24]  Rémi Thomas,et al.  Severe pneumonia due to Legionellapneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy , 2002, Intensive Care Medicine.

[25]  Marin H Kollef,et al.  Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. , 2002, Chest.

[26]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[27]  K. Garces.  Activated protein C for severe sepsis. , 2002, Issues in emerging health technologies.

[28]  M. Rybak,et al.  Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Claude D Martin,et al.  Empirical antimicrobial therapy of septic shock patients: Adequacy and impact on the outcome* , 2003, Critical care medicine.

[30]  P. Fulbrook,et al.  Care bundles in critical care: a practical approach to evidence-based practice. , 2003, Nursing in critical care.

[31]  M. Oh,et al.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  É. Azoulay,et al.  Improved survival of critically ill cancer patients with septic shock , 2003, Intensive Care Medicine.

[33]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[34]  J. Garnacho-Montero,et al.  Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis* , 2003, Critical care medicine.

[35]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[36]  Peter J Pronovost,et al.  Developing and pilot testing quality indicators in the intensive care unit. , 2003, Journal of critical care.

[37]  Stephan Harbarth,et al.  Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. , 2003, The American journal of medicine.

[38]  Herwig Gerlach,et al.  Fluid resuscitation in severe sepsis and septic shock: An evidence-based review , 2004, Critical care medicine.

[39]  J. Bartlett,et al.  Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. , 2004, Archives of internal medicine.

[40]  Margaret M Parker,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[41]  Allan R Tunkel,et al.  Practice guidelines for the management of bacterial meningitis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  Charles Natanson,et al.  Meta-Analysis: The Effect of Steroids on Survival and Shock during Sepsis Depends on the Dose , 2004, Annals of Internal Medicine.

[43]  Djillali Annane,et al.  Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis , 2004, BMJ : British Medical Journal.

[44]  Gary J Becker,et al.  The National Institute of General Medical Sciences. , 2005, Journal of the American College of Radiology : JACR.

[45]  B. Toye,et al.  Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. , 2005, QJM : monthly journal of the Association of Physicians.

[46]  R. Rossaint,et al.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005, The New England journal of medicine.

[47]  J. Krejčí,et al.  Right ventricular dysfunction in chronic heart failure patients , 2005, European journal of heart failure.

[48]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[49]  C. Natanson,et al.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly. , 2006, The New England journal of medicine.

[50]  G. Van den Berghe,et al.  Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.

[51]  P. Pronovost,et al.  An intervention to decrease catheter-related bloodstream infections in the ICU. , 2006, The New England journal of medicine.

[52]  Donald M Berwick,et al.  All-or-none measurement raises the bar on performance. , 2006, JAMA.

[53]  M. Bauer,et al.  Implementation of an evidence-based “standard operating procedure” and outcome in septic shock* , 2006, Critical care medicine.

[54]  J. Parrillo,et al.  Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department. , 2006, Chest.

[55]  Scott T. Micek,et al.  Before–after study of a standardized hospital order set for the management of septic shock* , 2006, Critical care medicine.

[56]  M. Singer.  The Surviving Sepsis guidelines: evidence-based ... or evidence-biased? , 2006, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[57]  Daniel Talmor,et al.  Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol* , 2006, Critical care medicine.

[58]  A. Delaney,et al.  Early goal-directed therapy of septic shock: we honestly remain skeptical. , 2007, Critical care medicine.

[59]  D. Cook,et al.  A survey of Canadian intensivists' resuscitation practices in early septic shock , 2007, Critical care.

[60]  E. Larson,et al.  Effectiveness of bundled behavioural interventions to control healthcare-associated infections: a systematic review of the literature. , 2007, The Journal of hospital infection.

[61]  L. Snyder,et al.  Pay-for-performance principles that promote patient-centered care: an ethics manifesto. , 2007, Annals of internal medicine.

[62]  Sumita Sinha,et al.  Seasonal variation in the epidemiology of sepsis* , 2007, Critical care medicine.

[63]  Alan E. Jones,et al.  Prospective external validation of the clinical effectiveness of an emergency department-based early goal-directed therapy protocol for severe sepsis and septic shock. , 2007, Chest.

[64]  P. Ray,et al.  Cardiac filling pressures are not appropriate to predict hemodynamic response to volume challenge* , 2007, Critical care medicine.

[65]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  J. Devlin,et al.  Factors Influencing Variability in Compliance Rates and Clinical Outcomes Among Three Different Severe Sepsis Bundles , 2007, The Annals of pharmacotherapy.

[67]  A central venous pressure goal of 8-12 mm Hg for all patients in septic shock. , 2007, Critical care medicine.

[68]  Robert Steele,et al.  Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality* , 2007, Critical care medicine.

[69]  P. Pronovost,et al.  Hemodynamic goals in randomized clinical trials in patients with sepsis: a systematic review of the literature , 2007, Critical care.

[70]  A. E. El Solh,et al.  Outcome of Septic Shock in Older Adults After Implementation of the Sepsis “Bundle” , 2008, Journal of the American Geriatrics Society.

[71]  P. Bollaert.  Corticosteroids for septic shock. , 2008, The New England journal of medicine.

[72]  R. Bellomo,et al.  The pursuit of a high central venous oxygen saturation in sepsis: growing concerns , 2008, Critical care.

[73]  M. Levy,et al.  Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. , 2008, JAMA.

[74]  Brian H Cuthbertson,et al.  Hydrocortisone therapy for patients with septic shock. , 2008, The New England journal of medicine.

[75]  Richard Beale,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2008 .

[76]  Marcus J Schultz,et al.  The incidence of low venous oxygen saturation on admission to the intensive care unit: a multi-center observational study in The Netherlands , 2008, Critical care.

[77]  A. Perel.  Bench-to-bedside review: The initial hemodynamic resuscitation of the septic patient according to Surviving Sepsis Campaign guidelines – does one size fit all? , 2008, Critical care.

[78]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[79]  Stephane Heritier,et al.  Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.